Aspire Biopharma Holdings, Inc.
ASBP
$1.06
-$0.14-11.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 126.32% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 126.32% | -- | |||
| Cost of Revenue | 381.82% | -- | |||
| Gross Profit | -211.11% | -- | |||
| SG&A Expenses | 86.30% | 109.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 61.56% | 43.44% | |||
| Operating Income | -61.45% | -43.21% | |||
| Income Before Tax | -154.40% | 6.60% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -154.40% | 6.60% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -154.40% | 6.60% | |||
| EBIT | -61.45% | -43.21% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -23.26% | 6.96% | |||
| Normalized Basic EPS | -23.26% | -13.98% | |||
| EPS Diluted | -23.26% | 6.96% | |||
| Normalized Diluted EPS | -23.26% | -13.98% | |||
| Average Basic Shares Outstanding | 106.40% | 0.39% | |||
| Average Diluted Shares Outstanding | 106.40% | 0.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||